Biosensors & bioelectronics · 2025
Ultrasensitive multifunctional biosensor integrating ECL quenching and DPV enhancement for early classification of thyroid cancer via BRAF V600E and microRNA-221 detection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yan, Ye Zhuoxin, Ma Mo, Wu Yongli, Chen Yuxuan, Liu Ruiyan, Ma Pinyi, Song Daqian
Аннотация
Papillary thyroid carcinoma (PTC) is the most prevalent form of thyroid cancer with a high incidence among endocrine malignancies. It tends to metastasize early in lymph nodes and differs markedly from other subtypes in biological behavior, clinical management, and prognosis. Therefore, accurately distinguishing PTC from other pathological subtypes is crucial for guiding diagnosis and treatment decisions. However, conventional methods such as thyroid ultrasound and ultrasound-guided fine-needle aspiration cytology (FNA) have limitations, including sampling errors and low sensitivity. To address these challenges, we developed a novel electrochemiluminescence (ECL) biosensor from CdTe-DNA quantum dots (QDs) and an enzyme-free DNA amplification circuit. In the system, toehold-mediated strand displacement reactions (TSDR) were utilized to generate Cy5-modified DNA strands, which quench the ECL signal via an energy transfer effect. The quenching indicates the presence of thyroid cancer. Catalytic hairpin assembly (CHA) was employed to produce ferrocene (Fc)-labeled DNA strands to enable dual-mode signal modulation (ECL quenching and differential pulse voltammetry (DPV) enhancement) for accurate classification of PTC. Validation experiments demonstrated that the biosensor exhibits excellent sensitivity and a broad dynamic range, enabling the simultaneous detection of BRAF V600E mutations and microRNA-221 (miR-221) expression. This integrated sensing platform offers is a promising tool for the early diagnosis and molecular classification of thyroid cancer.